Park Place Capital’s Royalty Pharma RPRX Stock Holding History

Park Place Capital’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$197K	Buy	3,510 +25	+0.7%	+$1.3K	0.03%	241
2026 Q1	$167K	Hold	3,485	–	–	0.03%	205
2025 Q4	$135K	Hold	3,485	–	–	0.03%	220
2025 Q3	$123K	Hold	3,485	–	–	0.03%	230
2025 Q2	$125K	Hold	3,485	–	–	0.03%	247
2025 Q1	$108K	Buy	+3,485	New	+$110K	0.03%	248
2024 Q4	–	Sell	-3,753	Closed	-$106K	–	866
2024 Q3	$106K	Sell	3,753 -65	-2%	-$1.8K	0.03%	281
2024 Q2	$101K	Sell	3,818 -1,250	-25%	-$34.6K	0.03%	275
2024 Q1	$154K	Sell	5,068 -588	-10%	-$17.3K	0.06%	264
2023 Q4	$159K	Buy	5,656 +1,939	+52%	+$53.3K	0.06%	248
2023 Q3	$101K	Hold	3,717	–	–	0.03%	342
2023 Q2	$114K	Hold	3,717	–	–	0.03%	324
2023 Q1	$134K	Sell	3,717 -72	-2%	-$2.67K	0.04%	299
2022 Q4	$150K	Buy	+3,789	New	+$158K	0.04%	281

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Park Place Capital's RPRX Position: Q2 2026 in Review

Park Place Capital increased its Royalty Pharma (RPRX) stake by 0.72% in Q2 2026, buying an estimated $1.3K and bringing the position to 3,510 shares worth $197K. The position accounts for 0.03% of the portfolio, ranked #241.

Park Place Capital first reported a position in RPRX in Q4 2022 and has held it in 14 quarters since. 645 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

Park Place Capital held 3,510 shares of Royalty Pharma worth $197K as of Q2 2026.
Park Place Capital bought 25 Royalty Pharma shares in Q2 2026, an estimated $1.3K.
Royalty Pharma made up 0.03% of Park Place Capital's portfolio in Q2 2026, its #241 holding.
Park Place Capital first reported a position in Royalty Pharma in Q4 2022 and has held it in 14 quarters since.
645 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Park Place Capital's 13F filing for Q2 2026, filed 14 Aug 2026.